This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Trabio

AstraZeneca PLC

Drug Names(s): lerdelimumab, CAT-152

Description: Trabio is a human anti-TGFß2 monoclonalantibody in development as an anti-scarring agent,particularly following eye surgery. TGFß2hyperactivity is associated with post-operativescarring in and around the eye. Post-operativescarring is the major reason for long-termophthalmologic surgical failure in these clinicalscenarios.

Deal Structure: Trabio was developed by Cambridge Antibody Technology (CAT). In June 2006, CAT became a subsidiary of AstraZeneca.


Trabio News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug